Ratio Therapeutics
Boston, US · Delaware corporation · 1 known investors
Ratio Therapeutics develops radiopharmaceuticals for oncology, working on targeted radiochemistry, discovery, and preclinical and clinical development. The company operates in the biotech and medtech space focused on molecular imaging and radiotherapy.
BiotechHealthtechMedical Devices
Founders & leadership
JW
John W. HoppinCo-founder
JB
John BabichDirector, President & Chief Scientific Officer
MB
Marc BeckerChief Financial and Operating Officer
SM
Scott MacDonaldNamed on SEC filing
WC
William CowanNamed on SEC filing
SW
Susan WhoriskeyNamed on SEC filing
AH
Albert HolmanNamed on SEC filing
AG
Allan GreenNamed on SEC filing
BI
Brandon IngersollNamed on SEC filing
JH
Jack HoppinChairman & Chief Executive Officer
WC
William CupeloChief Business Officer
MF
Matthias FriebeChief Technology Officer
Investors · 1
Reported raises · per SEC filings
Form D private placements$120.7M disclosed across 2 rounds · 2023–2026
▶$70MraisedJul 2026 · 57 investors · PharmaceuticalsRule 506(b)
▶$70MraisedJul 2026 · 57 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John W. HoppinExecutive Officer, Director
- John BabichDirector
- Marc BeckerExecutive Officer
- Scott MacDonaldExecutive Officer
- William CowanDirector
- Susan WhoriskeyDirector
- Albert HolmanDirector
- Allan GreenDirector
- Brandon IngersollDirector
- Offering amount
- $70M
- Amount sold
- $70M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50.7MraisedDec 2023 · 46 investors · PharmaceuticalsRule 506(b)
▶$50.7MraisedDec 2023 · 46 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Allan GreenDirector
- Shawn HillierExecutive Officer
- Albert HolmanDirector
- Matthias FriebeExecutive Officer
- John W. HoppinExecutive Officer, Director
- Jacob HestermanExecutive Officer
- John BabichExecutive Officer, Director
- Reed MalleckExecutive Officer
- Scott HolbrookDirector
- John GarveyExecutive Officer
- Susan WhoriskeyDirector
- Offering amount
- $50.7M
- Amount sold
- $50.7M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapAtara Biotherapeutics11 shared keywordsAtara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.
Bioworld11 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Aro Biotherapeutics10 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Relay9 shared keywordsRelay Therapeutics develops small-molecule therapeutics using its Dynamo platform, which combines experimental and computational methods to model protein motion and target proteins considered difficult to drug. Its pipeline focuses on precision oncology and genetic disease.
Companies competing with Ratio Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Ratio Therapeutics secures $70m in Series C funds for cancer radiotherapypharmaceutical-technology.com · Aug 2026
Eli Lilly (LLY) Backs Ratio Therapeutics In $70 Million Cancer Funding Round - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Ratio Therapeutics do?
- Ratio Therapeutics develops radiopharmaceuticals for oncology, working on targeted radiochemistry, discovery, and preclinical and clinical development. The company operates in the biotech and medtech space focused on molecular imaging and radiotherapy.
- Who founded Ratio Therapeutics?
- Ratio Therapeutics was founded by John W. Hoppin, John Babich.
- Who are Ratio Therapeutics's investors?
- Ratio Therapeutics's investors include Catalio Capital Management.
- How much funding has Ratio Therapeutics raised?
- Ratio Therapeutics has disclosed $120.7M raised across 2 rounds.
- Where is Ratio Therapeutics headquartered?
- Ratio Therapeutics is headquartered in Boston, US.